MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
GAITHERSBURG, Md., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of Jeffrey Stoddard, M.D., to the position of Vice President, Medical Affairs. Dr. Stoddard’s efforts will be focused on external engagement with thought leaders, vaccine experts, policymakers and key stakeholders. He will also be responsible for evidence generation related to health economics and outcomes research.
Dr. Stoddard joins Novavax with more than 15 years of vaccine research and development experience and leadership roles. He was instrumental in the commercial launch of multiple vaccines and biologics including Synagis®, FluMist®, pandemic flu vaccines, Menveo® and Bexsero®. He was most recently Vice President, Medical Affairs & Medical Professional Services, at Alkermes plc, where he led medical affairs, and health economics and outcomes research. Prior to Alkermes, Dr. Stoddard held positions of increasing responsibility at Novartis Vaccines, Covance and MedImmune. Dr. Stoddard earned his medical degree from the University of Wisconsin Medical School, a Bachelor of Science degree from the University of Wisconsin-Madison, and completed a residency at Johns Hopkins Hospital and a postdoctoral fellowship in the Pew Health Policy program at the University of California, San Francisco.
“Dr. Stoddard is a foundational building block of the Novavax commercial team,” said John Trizzino, Senior Vice President, Commercial Operations. “His medical and healthcare policy experience will be critical as we develop our disease state awareness and vaccine policy strategy and we look forward to his leadership in educating healthcare providers in anticipation of the commercial launch of our respiratory syncytial virus F-protein nanoparticle vaccine candidate.”
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company’s website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
